Alopecia areata
Conditions
Interventions
A within-patient double blind (patient and examiner) randomized controlled trial was performed. Twelve patients with clinical diagnosis of localized alopecia areata, with plaque measuring 2 to 5 cm we
Drug
D04.210.500.745.432.769.199
Sponsors
Universidade Federal do Ceará, Campus Sobral
Universidade Federal do Ceará, Campus Sobral
Eligibility
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: both genders; age between 18 and 60 years; clinical diagnosis of localized alopecia areata, with less than 25% area of hair loss; presence of an alopecia patch with a larger diameter between 2 and 5 cm
Exclusion criteria
Exclusion criteria: any form of therapy for alopecia areata in the past 3 months; use of systemic corticosteroids or immunosuppressive drugs; illness or condition that causes immunosuppression; rapidly progressive disease; presence of another cause of alopecia; presence of an inflammatory process in the alopecia patch; history of allergy to corticosteroids; pregnancy or lactation
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinically evaluate the repilation during treatment with intralesional betamethasone diluted to 0.375mg / ml and 1.75mg / ml, when compared to intralesional triamcinolone at 2.5mg / ml and placebo, applied in four quadrants of the same lesion. We used the photographic comparison between the quadrants of each patient, individually, in order to determine the intervention with the best therapeutic response for each participant, at weeks 4, 8 and 12.This assessment aimed to determine different responses to treatment, when comparing the quadrants of the same patient's lesion, which can be perceived macroscopically by the researcher, regarding the repilation process. To record the response, a standardized scale of 0 to 4 degrees of repilation was used. At 4 and 8 weeks of intervention, triamcinolone acetonide 2.5 mg/ml provided the best visual results. Nevertheless, at the end of the study, the best visual results were seen with both triamcinolone acetonide and betamethasone 1.75mg/ml, with significant difference when compared to betamethasone 0.375mg/ml and placebo (p 0.0489 and less than 0.0001, respectively). | — |
Secondary
| Measure | Time frame |
|---|---|
| We quantified the number of dystrophic hair, markers of disease activity, before each intervention, in each quadrant, every 4 weeks. They were considered dystrophic: yellow dots, black dots, broken hair, exclamation hair, elbow hair and Pohl Pinkus constriction. We performed dermoscopy with a dermlite DL3® manual dermoscope (3Gen, U.S.A., Inc) and analyzed the dermoscopy image at weeks 4, 8 and 12. For this record, the ImageJ® imaging software was used. There was a progressive reduction in the number of dystrophic hairs in all intervention quadrants and placebo; however, most patients achieved a significant reduction (75%) more rapidly in the triamcinolone-treated quadrant. | — |
Countries
Brazil
Contacts
Public ContactVando de Sousa
Universidade Federal do Ceará, Campus Sobral
Outcome results
None listed